<DOC>
	<DOCNO>NCT00569803</DOCNO>
	<brief_summary>Pharmacokinetics , Bioavailability , Safety Immunogenicity Single Doses Belatacept Administered Subcutaneously Healthy Subjects</brief_summary>
	<brief_title>Subcutaneous Pharmacokinetics Belatacept</brief_title>
	<detailed_description />
	<mesh_term>Abatacept</mesh_term>
	<criteria>Men woman age 18 65 year old Subjects must weigh less equal 100 kg Inability tolerate injection IV infusion autoimmune disorder TB herpes HCV HBV HIV bacterial viral infection history cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>